Transplant Surgery »  Faculty »  Hepatology »  Norah A. Terrault, M.D., M.P.H.

Norah A. Terrault, M.D., M.P.H.

Professor of Clinical Medicine & Surgery
Departments of Medicine & Surgery
Director of Viral Hepatitis Research in Liver Transplantation

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 476-2227
415-476-0659
norah.terrault@ucsf.edu
 
  • 1985 B.MSc., University of Alberta
  • 1987 M.D., University of Alberta
  • 1997 M.P.H. University of California, Berkeley
  • 1987-88 Internship, University of Toronto
  • 1988-91 Internal Medicine, University of Toronto
  • 1991-93 Gastroenterology, University of Toronto
  • 1994-95 Clinical Hepatology, Division of Gastroenterology, University of Toronto

  • 1995-97 Research Hepatology, Division of Gastroenterology, UCSF Medical Center

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Gastroenterology
  • UCSF Liver Center
  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Liver Injury and Repair

Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.

Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation. 

Most recent publications from a total of 196
  1. Campos-Varela I, Straley S, Agudelo EZ, Carlson L, Terrault NA. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl. 2015 Feb; 21(2):272-4. View in PubMed
  2. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg? Hepatology. 2015 Feb; 61(2):703-11. View in PubMed
  3. Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge JL, Roberts JP, Terrault NA, Feng S. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. Liver Int. 2015 Jan 28. View in PubMed
  4. Goel A, Terrault N. Reply. Liver Transpl. 2015 Mar; 21(3):416. View in PubMed
  5. Price JC, Terrault NA. Treatment of Hepatitis C in Liver Transplant Patients: Interferon OUT, Direct Antiviral Combos IN. Liver Transpl. 2015 Jan 20. View in PubMed
  6. Lai JC, Shoback DM, Zipperstein J, Lizaola B, Tseng S, Terrault NA. Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci. 2015 Jan 7. View in PubMed
  7. Tejada-Strop A, Drobeniuc J, Mixson-Hayden T, Forbi JC, Le NT, Li L, Mei J, Terrault N, Kamili S. Disparate detection outcomes for anti-HCV IgG and HCV RNA in dried blood spots. J Virol Methods. 2015 Feb; 212:66-70. View in PubMed
  8. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82. View in PubMed
  9. Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17. View in PubMed
  10. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Norah A. Terrault, M.D., M.P.H.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X